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Abstract: Current reported incidence rates for ovarian cancer may significantly underestimate the
true rate because of the inclusion of women in the calculations who are not at risk for ovarian cancer
due to prior benign salpingo-oophorectomy (SO). We have considered prior SO to more realistically
estimate risk for ovarian cancer. Kentucky Health Claims Data, International Classification of Disease
9 (ICD-9) codes, Current Procedure Terminology (CPT) codes, and Kentucky Behavioral Risk Factor
Surveillance System (BRFSS) Data were used to identify women who have undergone SO in Kentucky,
and these women were removed from the at-risk pool in order to re-assess incidence rates to more
accurately represent ovarian cancer risk. The protective effect of SO on the population was determined
on an annual basis for ages 5–80+ using data from the years 2009–2013. The corrected age-adjusted
rates of ovarian cancer that considered SO ranged from 33% to 67% higher than age-adjusted rates
from the standard population. Correction of incidence rates for ovarian cancer by accounting for
women with prior SO gives a better understanding of risk for this disease faced by women. The rates
of ovarian cancer were substantially higher when SO was taken into consideration than estimates
from the standard population.
Keywords: ovarian cancer; prevalence; incidence; oophorectomy; screening
1. Introduction
Cancer incidence rates are calculated by dividing new primary cancer cases of a disease by the
population at risk in the same time period adjusted by the US standard population [1]. This assessment
has great importance clinically, especially for gynecologic oncology with regard to training a sufficient
number of physician specialists. Cancer incidence rates help physicians and researchers assess risk
levels, which can be used for public health and individual patient education, to prioritize prevention
and research efforts, and to guide assessment of the cost and efficacy of cancer screening. Thus, the
accuracy of this risk assessment is very important.
There is an inherent problem in the incidence calculation for some malignancies due to the
inclusion of patients in the denominator who are not at risk for the disease [2]. In gynecologic oncology,
this has been most thoroughly evaluated in the case of endometrial cancer and hysterectomy. Many
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women will undergo hysterectomy in their lifetime for a variety of benign conditions [3,4]. These
women are not at risk for developing endometrial cancer after uterine removal and should not be
included in the population at risk for incidence rate calculation. There have been multiple publications
that have evaluated methods of correcting risk calculations for endometrial cancer. In 2012, Siegel et al.
reported on age-adjusted, hysterectomy-corrected uterine cancer rates stratified by race and geography
and found that failure to adjust rates for hysterectomy leads to distortion of racial and geographic
patterns and underestimates disease burden [5].
There is less guidance in the literature concerning the impact of oophorectomy rates on ovarian
cancer incidence. Many women have salpingo-oophorectomy (SO) performed alone due to benign
ovarian disease, or have SO performed at the time of hysterectomy for benign conditions. There has
been new evidence linking the origin of serous ovarian cancer to the fimbriated end of the fallopian
tube [6–17]. During adnexal surgeries, the tube is usually removed concurrently with the ovary.
Whether the pathogenesis for the most common type of ovarian cancer truly arises from the distal
tube or the ovary itself, those who have undergone SO should have drastically reduced risk of
this type of malignancy. This reduction has been demonstrated in high risk women with Breast
Cancer Susceptibility (BRCA) mutations who undergo risk-reducing salpingo-oophorectomy and have
dramatically lower risk of ovarian malignancy [16–19].
The current reported incidence of ovarian cancer from 2005–2009 is 12.7 per 100,000 women [20].
Incidence rates are higher in whites and the average age at diagnosis is 63 [20]. Lifetime risk of
developing ovarian cancer in the United States is 1.4% [20]. In 2016, 22,280 new cases were expected
and 14,240 deaths anticipated from this disease [21]. Ovarian cancer is the 5th leading cause of death
from malignancy in women in this country due to the fact that the majority of cases are diagnosed at
an advanced stage. Research into prevention and screening for ovarian cancer is hampered by this low
prevalence, which negatively affects accurately estimating the positive predictive value for these tests.
We hypothesize that when incidence rates are corrected for prior SO, incidence of this disease will be
higher than in commonly reported statistics which currently underestimate the risk of ovarian cancer
for women whose ovaries and/or tubes remain intact.
2. Materials and Methods
2.1. Cancer Incidence Data
To calculate the cancer incidence rates, the most recent five-year ovary cancer cases diagnosed in
years 2009–2013 from the Kentucky Cancer Registry (KCR) were extracted. Ovary cancer cases were
defined as ICD-O-3 site codes C569 excluding ICD-O-3 histology codes 9050–9055, 9140, 9590–9992.
Only invasive cancer cases were included for the analysis.
The KCR is a population-based registry, and has been awarded the highest level of certification
by the North American Association of Central Cancer Registries for an objective evaluation of
completeness, accuracy, and timeliness every year since 1997. The KCR is part of both the CDC
National Program of Cancer Registries and the NCI Surveillance, Epidemiology, and End Results
(SEER) program, which are considered among the most accurate and complete population-based cancer
registries in the world. The KCR also links its database annually with the National Death Index (NDI)
to capture the most accurate survival information. No new data was collected from subjects specifically
for this study and no contact with any patients was required. All data was previously de-identified.
2.2. Kentucky Health Claims Data (KHCD)
In order to correctly calculate the age-adjusted rates for ovary cancer incidence, the underlying
risk population needs to be modified to reflect the fact that women who had SO will have minimal risk
of having ovarian cancer. To estimate the prevalence of women who had prior SO for years 2009–2013
in Kentucky, the Kentucky health claims data (KHCD) 2000–2014 data sets were acquired from the
Office of Health Policy in the Kentucky Cabinet for Health and Family Services (KCHFS).
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The KHCD data include hospital discharge reports from all Kentucky hospitals, Medicare
provider-based entities and ambulatory facilities (http://lrc.ky.gov/KAR/900/007/030.htm). The data
include in-patient and out-patient files containing de-identified individual records. Key elements, such
as ICD-9 procedure codes, CPT codes, and demographics are included in the files. Age is presented in
the format of age groups.
2.3. Kentucky Behavioral Risk Factor Surveillance System (BRFSS) Data
The Behavioral Risk Factor Surveillance System (BRFSS) data is the annual telephone survey
that collects state data related to health risk behavior, chronic health conditions, and use of
preventive services for all 50 states, the District of Columbia, and three territories in the U.S
(https://www.cdc.gov/brfss/). For women aged 18 and older, responses to the question “Have you
had a hysterectomy?” are included. The data related to this question was used to estimate the
prevalence of prior hysterectomy by age group. Since the hysterectomy question was presented every
other year, the Kentucky BRFSS data 2008–2012 was acquired from the KCHFS to match the ovary
cancer incidence data 2009–2013.
2.4. Estimating Oophorectomy Prevalence
To estimate the prevalence of prior SO for Kentucky women in 2009–2013, two approaches were
used. The first method estimated the full SO prevalence rates directly from the KHCD data and the
second method estimated the SO prevalence rates based on both BRFSS data and KHCD data.
In the first method, SO cases were identified by ICD-9 procedure codes and CPT codes from
the KHCD data for the years 2000–2014. Since the KHCD data in 2000–2003 did not include age or
CPT codes and 2014 data were beyond the study period, only data for years 2004–2013 were used
for the data analysis. The combined counts of SO cases by year and age group from both in-patient
and out-patient files were considered as the total SO incidence. The age groups in KHCD data were
categorized as 0, 1–5, 6–10, . . . , 76–80, 81+ years. Statistical approaches to estimating prevalence
from incidence data commonly involves mortality and survival data, and can be either parametric
or non-parametric [22–25]. Counting Method, a non-parametric approach, was used to estimate
prevalence of prior SO based on the SO incidence data from the KHCD [23]. This approach counts
cases of ‘still alive’ individuals on the desired prevalence date while making adjustment based on the
estimates of cases lost to follow-up. For example, the number of prevalence case in age i and calendar
year j was estimated as
Nij =
∫ i
0
I(t)S(t, i − t)dt
where I(t) is the number of incidence in age t, and S(t, i − t) is the survival probability from all causes
from age t to i − t. Since the KHCD data do not include survival and mortality data, the US 2010
female life tables were used to estimate the survival probabilities from all causes in the specific years
and age groups. Bridged life tables to match the age group defined in the KHCD were calculated from
the complete US 2010 female life table [26]. Because no SO incidence data by age group were available
prior to 2004, it was assumed that the incidence data prior to 2004 were same as in the average of
2004–2013. To understand the impact of the assumption, the same calculation was also done while
assuming incidence data prior to 2004 was the same as in the year 2004 and the year 2012, as the
highest count of prevalence was identified in year 2004 and the lowest in 2012. To reflect the fact that
the US life expectancies have increased over time and that women with oophorectomy had lower life
expectancies than the general population [27], the probability of survival estimates were lowered from
values in the US life tables by 0.5% when calculating the complete prevalence rates for prior SO.
To validate the prevalence estimates from the first method, we also used the BRFSS data to
estimate the prevalence rates. In previous published studies, prevalence rates of prior SO were
estimated by multiplying the prevalence rates of hysterectomy from the BRFSS data by the proportion
of hysterectomy incidences with bilateral oophorectomy [2]. Similarly, we calculated the ratio of SO vs.
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hysterectomy by age group from the KHCD data for years 2004–2013 and the weighted prevalence
rates of prior hysterectomy by age group for those aged 20+ from the BRFSS data for 2008, 2010
and 2012. The prior SO prevalence estimates by age groups were the product of the ratio of SO vs.
hysterectomy and the prevalence of prior hysterectomy from the BFRSS data.
2.5. Age-Adjusted Incidence Rates for Ovary Cancer
All age-adjusted rates were calculated based on the standard 2000 US population. To examine
how the different formats of age groups in the background population impact age-adjusted rates, the
traditional age-adjusted rates based on the 19 age groups in the standard Kentucky population were
calculated along with the traditional age-adjusted rates based on the 18 age groups defined in the
KHCD data. To calculate the corrected age-adjusted rates for ovary cancer, the standard Kentucky
population data were corrected by deducting the number of women with SO derived through the
prevalence estimates from the two approaches previously discussed.
All analyses were done using SAS Statistical software version 9.4. SAS (SAS Institute, Cary, NC,
USA) was also used to develop programs to calculate the complete prevalence rates from the KHCD
data. Statistical tests were two sided with a p-value ≤ 0.05 used to identify statistical significance.
3. Results
There was a total of 81,359 SO cases identified from the KHDC data during 2004–2013 (Table 1).
The highest frequencies were found in the age groups 41–45 and 46–50. Very few cases were found in
women with ages younger than 20 or ages older than 80. The number of SO cases from the inpatient
files had dropped steadily over the study period and the number of cases from the outpatient files had
increased. The overall SO cases had consistently dropped since 2003 (Figure 1).
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Figure 1. Trend of salpingo-oophorectomy (SO) cases from the Kentucky Hospital Discharge
Data, 2004–2013.
Using the Counting Method, estimates of annual prevalence counts and rates by age group for the
years 2009 to 2013 were calculated from the KHCD. Only results from the years 2009 and 2013 based
on the assumption that SO incidences prior 2004 are same as the average in 2004–2013 are shown in
Table 2. The results based on the assumptions that SO incidences prior 2004 are same as in 2004 or
2012 can be found in Tables S1 and S2. The prevalence rates increased by age and peaked at the oldest
age groups of 76–80 an 81+. Because of the decreasing trend of SO cases, the prevalence rates had
dropped from year 2009 to 2013. For example, the rates dropped from 27.4% to 24.4% in the age group
61–65 and from 42.1% to 38.1% in the age group 71–75 (Table 2).
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Table 1. Salpingo-oophorectomy (SO) cases in Kentucky Hospital Discharge Data by age group, 2004–2013.
Year
Age Group
0 1–5 6–10 11–15 16–20 21–25 26–30 31–35 36–40 41–45 46–50 51–55 56–60 61–65 66–70 71–75 76–80 81 and over Total
2004 1 1 0 6 24 179 561 966 1482 2077 1919 987 445 356 265 202 142 79 9692
2005 0 1 1 7 24 191 542 887 1342 1999 1874 935 501 323 242 179 121 80 9249
2006 0 0 0 6 24 184 536 954 1308 1798 1662 894 500 365 277 201 142 87 8938
2007 1 0 1 5 31 193 500 833 1299 1669 1625 923 574 371 233 200 119 96 8673
2008 0 0 1 6 26 172 462 769 1119 1549 1512 832 486 382 306 179 124 86 8011
2009 1 2 0 8 38 147 500 771 1123 1530 1509 851 500 436 291 182 119 89 8097
2010 0 0 0 10 32 162 454 783 1075 1327 1373 828 479 384 265 198 112 75 7557
2011 2 1 2 12 40 155 411 764 1008 1241 1288 777 473 416 310 182 72 67 7221
2012 0 0 0 6 31 130 363 699 941 1185 1205 781 488 391 274 191 94 72 6851
2013 0 0 0 9 27 122 366 726 1031 1256 1188 748 518 425 307 186 103 63 7075
Total 5 5 5 75 297 1635 4695 8152 11,728 15,631 15,155 8556 4964 3849 2770 1900 1148 794 81,364
Table 2. Estimated SO Prevalence in Kentucky for year 2009 and 2013, by age groups *.
Age Group Prob. of Survival
2009 2013
Population Prevalence Count Prevalence Rate Population Prevalence Count Prevalence Rate
0 0.989 27,302 1.0 0.000 26,905 0.0 0.000
1–5 0.995 138,333 2.2 0.000 135,862 1.0 0.000
6–10 0.995 137,647 4.8 0.000 138,692 3.8 0.000
11–15 0.995 137,317 23.2 0.000 139,204 32.4 0.000
16–20 0.995 146,960 128.7 0.001 138,987 134.5 0.001
21–25 0.995 139,412 689.7 0.005 154,076 596.8 0.004
26–30 0.994 143,447 2624.1 0.018 137,250 2201.0 0.016
31–35 0.994 135,456 6206.3 0.046 142,561 5680.1 0.040
36–40 0.994 145,489 11,649.2 0.080 135,750 10,662.2 0.079
41–45 0.993 150,939 19,138.6 0.127 146,947 17,331.1 0.118
46–50 0.992 164,356 27,186.7 0.165 154,584 25,180.5 0.163
51–55 0.991 159,697 31,613.2 0.198 163,369 31,226.4 0.191
56–60 0.989 142,234 32,472.1 0.228 153,709 33,146.2 0.216
61–65 0.987 118,111 32,339.0 0.274 134,958 32,887.2 0.244
66–70 0.982 92,015 31,612.5 0.344 106,051 31,852.8 0.300
71–75 0.974 71,219 30,014.6 0.421 78,893 30,093.7 0.381
76–80 0.960 58,333 27,272.4 0.468 58,703 27,192.7 0.463
81+ 0.911 84,869 39,805.1 0.469 87,494 39,812.0 0.455
* Assume SO incidence prior 2004 same as the average of incidence between years 2004–2013.
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In Table 3, hysterectomy prevalence rates by age group were calculated from the BRFSS data
for 2008, 2010, and 2012. The highest rates appeared in the age group 76–80. Ratios of SO vs.
hysterectomy from the KHCD data varied from 65% to 103% by age group. The prior SO prevalence
rates modified from the hysterectomy rates from the BRFSS data peaked in the age group 66–70 (50.7%)
and were considerably smaller in the age group 81+ (42.5%) compared to the prevalence rates from the
Counting Method.
Table 3. Estimated hysterectomy and oophorectomy prevalence based on the Kentucky BRFSS data
and discharge data.
Age Group Hysterectomy PrevalenceRate by BRFSS ˆ
Ratio of SO vs.
Hysterectomy *
SO Prevalence
Rate by BRFSS
21–25 0.000 0.902 0.000
26–30 0.024 0.723 0.018
31–35 0.076 0.665 0.051
36–40 0.120 0.649 0.078
41–45 0.196 0.719 0.141
46–50 0.256 0.879 0.225
51–55 0.379 1.010 0.383
56–60 0.415 1.033 0.429
61–65 0.461 1.021 0.471
66–70 0.513 0.988 0.507
71–75 0.517 0.963 0.498
76–80 0.532 0.900 0.479
81+ 0.512 0.829 0.425
ˆ Estimated hysterectomy prevalence based on the KY BRFSS data, 2008–2012; * Ratio of SO vs. hysterectomy in
Kentucky discharge data from year 2004 to 2013.
A total of 1403 invasive ovary cancer cases for years 2009–2013 were extracted from the KCR
database. The age-adjusted rates from the standard Kentucky population show the rates 10.7 per
100,000 (95% Confidence Interval (CI) 10.2–11.3) for all ages (Table 4). To match the age groups defined
in the KHCD data, the age adjusted rates based on the standard Kentucky population with modified
age groups were also calculated. The corrected age-adjusted rates from adjusting the population under
risk based on the prevalence estimates of prior SO from the KHCD data were 15.5 (95% CI 14.7–16.3)
per 100,000 assuming SO incidences prior 2004 were the same as the average of the incidence in the
years 2004–2013, 16.9 (95% CI 16.0–17.8) per 100,000 assuming the SO incidences prior to 2004 were
the same as in 2004 (highest incidence), and 14.3 (95% CI 13.6–15.1) per 100,000 assuming the SO
incidences prior to 2004 were the same as in 2012 (lowest incidence). The corrected age-adjusted
rate from the BRFSS prevalence estimates of SO was 17.7 (95% CI 16.8–18.7), which is higher than
the highest estimates from the KHCD data (16.9 per 100,000). Overall, risk population adjusted SO
age-adjusted rates ranged from 33% to 65% higher than the rates from the standard population. We also
included the age-specific rates for ovary cancer by various approaches in Table S3.
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Table 4. Age adjusted rates for invasive ovary cancer in Kentucky, 2009–2013.
Type of Population Under Risk
All Ages
Population under Risk N Adj Rate 95% CI
Standard Population ˆ 11,083,781 1403 10.73 10.16 11.32
Standard Population with Modified Age Group * 11,083,781 1403 10.73 10.17 11.32
Modified Population based on KCHD-Assumption 1 ~ 9,630,865 1403 15.47 14.65 16.32
Modified Population based on KCHD-Assumption 2 ~ 9,414,282 1403 16.88 15.98 17.82
Modified Population based on KCHD-Assumption 3 ~ 9,847,449 1403 14.34 13.58 15.12
Modified Population based on BRFS † 9,009,436 1387 17.72 16.78 18.69
ˆ The standard 19 population age groups, 0, 1–4, 5–9, . . . , 80–84, 85+; * Use the 18 age groups in the hospital
discharge data, 0, 1–5, 6–10, . . . , 76–80, 81+; ~Adjusted the standard population based on the prevalence rates
from the Kentucky Health Claims Data; Assumption 1: Assume incidence prior to2004 same as the average in
year 2004–2013; Assumption 2: Assume incidence prior to 2004 same as the average in year 2004; Assumption 3:
Assume incidence prior to 2004 same as the average in year 2012; † Adjusted the standard population based on the
prevalence rates from BRFSS data.
4. Discussion
In the efforts reported here, the rates of ovarian cancer were 33% to 65% higher when prior SO was
taken into consideration than estimates from the standard population. Due to the limitation of data
availability, the risk-population adjusted prior SO rates have rarely been calculated previously. In the
current study, we used the KHCD data and the Counting Method, a modern statistical approach, to
estimate the prior SO prevalence rates based on various assumptions and the risk-population adjusted
SO rates. We also estimated the SO rates using estimated SO prevalence rates from the BRFSS data.
The prevalence rates of prior SO from the Counting Method and the BRFSS data are different because
of various assumptions and different data sources, hence leading to the variation of the risk-population
adjusted SO rates. The results demonstrate the challenge to correctly estimate the rates because of the
data limitations.
Compared to previous published studies with only one type of estimate [2], our study is able
to provide a range of estimates that gives a more comprehensive view of the estimates. It is possible
that the 0.5% survival deduction of probability of annul survival from the standard US life table was
too harsh and caused the lower estimates of SO prevalence rates compared to the estimates from the
BRFSS data. Using the ratio of SO vs. hysterectomy from the KHCD data to estimate SO prevalence
rates from the BRFSS was likely biased as the ratio was based on incidence data, not prevalence data.
Ovarian cancer remains the deadliest gynecologic malignancy in the United States, being the 5th
most common cause of cancer death in women. Over 14,000 deaths from ovarian cancer are expected
for the US in 2016 [20]. Despite advances in operative care and chemotherapy, including the recent use
of targeted agents for this disease, overall survival remains poor [20,28–30]. While ongoing research
efforts continue to search for better treatments with which to combat this disease, another approach
to improve survival is through screening and earlier detection of disease. The majority of ovarian
cancer cases are diagnosed at advanced stage prior to the onset of symptoms. Pelvic exam has been
shown to have limited value in detecting ovarian abnormalities, especially in postmenopausal and
obese women [31]. Only 15% of cases are confined to the ovary at the time of diagnosis [32]. However,
survival is much improved for women who are diagnosed at an early stage [26]. Therefore, efforts to
increase the detection of early stage disease have a potential to greatly impact survival. Estimates that
reveal the true risk of ovarian cancer will support efforts to screen for early stage disease.
Screening for malignancy has been highly effective for other common malignancies such as
breast and cervix cancers [33,34]. Ovarian cancer meets criteria as a disease that could benefit from
effective screening since it is the 5th leading cause of cancer mortality in women with proven improved
survival when diagnosed at an earlier stage [20,26]. Screening has been studied in ovarian cancer,
most commonly with serum Ca125 levels and transvaginal ultrasound (TVUS) or a combination of
the two [35,36]. There have been four major trials that have evaluated ovarian cancer screening.
The first of these is the prostate, lung, colorectal, and ovarian (PLCO) trial, which showed no benefit to
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screening [37]. There was a multicenter prospective randomized trial in Japan that compared screening
with pelvic exam, serum Ca125, and ultrasound to routine care and saw an increase in the rate of
optimal debulking in the screen detected cancers [38]. Optimal debulking has a known association
with improved survival in ovarian cancer [39]. The University of Kentucky Ovarian Cancer Screening
Trial (UKOCST) has been in progress since 1987 [40,41]. Over 45,000 women have been screened to date
with TVUS. Detection of 47 ovarian cancers has been reported by the UKOCST and these women have
improved five-year survival and are more likely to be early stage than women with clinically detected
cancers [29,34,42]. Most recently, the results of the UKCTOCS randomized trial were published in the
Lancet and have shown a survival benefit for screening [30].
Taken together, the available data from these four trials suggests screening works to detect disease
at an earlier stage, which leads to improved survival. However, one of the most common criticisms
of screening and the studies that have evaluated it is the lower positive predictive values, which are
likely driven by the lower prevalence of this disease. Statistical calculations for predictive values vary
greatly depending on the prevalence of the disease being studied, unlike sensitivity and specificity
of a test, which remain constant. Thus, a test with inherently good sensitivity and specificity can be
brought to improved predictive ability by narrowing the screening population to a high-risk group for
which the prevalence is high.
One way to narrow threat risk population for ovarian cancer is by focusing on ages at which
incidence is high. This has been commonly applied in previous screening trials and the results of the
work reported here confirm the importance of age. In the present study, ovarian cancer incidence is
highest for women over age 75, while the rate of hysterectomy peaks at age 65. Age continues to be
one of the most important risk factors for ovarian cancer.
Given the importance of correct incidence to predictive calculations for screening programs and
epidemiologic risk assessment, an accurate calculation of incidence is critical. An accurate assessment
of risk is more easily determined in some diseases than others. If all subjects are at risk, then the
calculation is a straight forward division of those diagnosed with disease by those at risk. This is
not so clear in all diseases, however. For example, surgical interventions for unrelated problems
can reduce the at-risk pool for certain disease sites. This has been demonstrated in the literature
regarding endometrial cancer [5,43]. Correcting risk rates for endometrial cancer involves reducing
threat risk pool (or denominator of the calculation) by removing those women who have undergone
prior hysterectomy for a benign condition. Ignoring hysterectomy underestimates the risk for women
who have not undergone that procedure and has also been shown to distort data regarding the
distribution of disease [44]. Hysterectomy has recently been declining in nationwide statistics for the
US, but remains one of the most common procedures performed in this country today, which alters the
epidemiology significantly for uterine derived cancer risk [38]. Approximately 600,000 hysterectomies
are performed each year in the United States, and around a third of all women have had the procedure
by the time they turn 60 [45–47].
Salpingo-oophorectomy (SO) is even more difficult to quantify than hysterectomy. Many women
elect to have their ovaries and tubes removed at the time of a hysterectomy that is performed for a
variety of reasons related to primary uterine pathologies. Additionally, many women undergo bilateral
SO either separate from a hysterectomy or at some time after a hysterectomy has been performed
for a wide variety of primary ovarian or other conditions, many of which are benign. These include
endometriosis, non-cancerous ovarian cysts or masses, risk reduction for genetic conditions, and for
hormone reduction in breast cancer patients. The overall trend for SO in the US has been on the
decline [48]. This decline coincides with the similar decline in hysterectomy rate. This decline may
also be a result of data showing that surgical menopause prior to age 50 in women who never used
estrogen is associated with increased all causes mortality [49]. Despite this, the rates of SO remain
significant [42].
Given the robust number of women who have undergone SO, risk of ovarian cancer is greatly
reduced for these women and importantly alters the epidemiology of risk for malignancy at this site
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on a population level. There are some important caveats to this reduction. Serous peritoneal cancers
behave nearly identically to ovarian cancer and the risk for these cancers is unlikely to be altered
by SO [50]. It should be noted that peritoneal cancer is quite rare. The protective effect of SO is
illustrated in high risk women who have undergone prophylactic SO for BRCA mutation, and have
achieved a drastically reduced risk of serous malignancy [16–19]. In one study, the relative risk of
ovarian, fallopian tube or peritoneal carcinoma in women with known BRCA mutations after risk
reducing bilateral SO was 0.04 (95% CI 0.01–0.16) [18]. Recent literature supports two separate types
of ovarian malignancy, with separate pathogenesis [6–17]. Type 1 tumors are generally considered
low grade malignancies that arise from the epithelium of the ovaries. Type 2 cancers generally include
high grade serous malignancies that are felt to arise from the distal, fimbriated end of the fallopian
tube. The fallopian tube is generally removed with the ipsilateral ovary in most procedures that are
performed—few indications, if any, would preserve the tube if the ovary is being removed. Thus,
protection from Type 2 ovarian malignancy is gained from ovarian removal in most cases since the
tube is removed concomitantly (i.e., a salpingo-oophorectomy is typically performed rather than an
oophorectomy alone).
An additional consideration is that there is a rising trend in bilateral salpingectomy rather than
bilateral salpingo-oophorectomy, which allows ovarian preservation while still potentially reducing
cancer risks [42]. The degree to which this procedure is as protective as SO has yet to be determined.
The current study takes into account women having SO but not salpingectomy alone. An argument
can be made to include these patients for future studies, which has the potential to further correct the
underestimation of the prevalence of ovarian cancer for women who retain all portions of their adnexa.
Overall, the SO rate nationally has been reported to be declining. However, it is still common
for women to undergo this procedure and greater than 40% of women still undergo bilateral SO at
the time of hysterectomy [42,51]. This significant rate needs to be taken into account for estimating
accurate ovarian cancer incidence. Failing to recognize and account for the population of women
no longer at risk underestimates the incidence for the rest of the population. This was the driving
motivation for the current study and the results confirm that incidence rates need to take surgical
procedures into account. Incidence is certainly higher by all methods used for calculation in this study
once SO was taken into account. This was true both with overall incidence across ages, as well as
age-adjusted groups.
There is inherent difficulty in establishing the overall risk associated with SO. Prior
studies have shown an overall mortality disadvantage for women who undergo premenopausal
oophorectomy—prior to age 50—and never used estrogen therapy [43]. This decrease in lifespan may
be attributed to changes in cardiovascular health and other important roles provided through the
hormonal functions of the ovary. How this risk quantitatively translates to changes in expected lifespan
on an annual statistical level is unclear. This study estimated decreased survival of 0.5% annually for
women who had undergone premenopausal SO. However, these are estimates and the true annual
change in expected survival is unknown. Even taking this into account though, all calculations still
show that incidence is underestimated if SO is not taken into account when evaluating ovarian cancer.
The strengths of this study include the use of population level data and novel statistical evaluation
to correct risk assessments in an important way for women with regard to ovarian cancer. A couple
of limitations are worth noting. Most notably, this study is limited by the dependence on CPT
and ICD codes for diagnosis. Actual operative reports or pathology reports were not available for
confirmation of procedure performed. This introduces the possibility of inappropriate coding leading
to incorrect inclusion (or exclusion) of patients in the analysis. In addition, newer ICD codes are more
specific in that bilateral procedures are noted and were isolated for inclusion. This is important as
unilateral procedures would not be expected to confer the same protection against ovarian cancer as
the remaining ovary and/or tube could lead to a malignancy. Not all CPT codes separate unilateral
from bilateral procedures and thus there is some uncertainty on the extent of adnexal removal with
patients coded this way. Also, some hysterectomy codes are nonspecific as to inclusion of adnexal
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removal or not. Most notably, abdominal hysterectomy CPT codes can include patient “with or
without” adnexal removal. Thus, using these codes can contribute uncertainty to the study as the true
proportion of patient with adnexal removal with hysterectomy is not indicated by the code. About
30% of the procedures included in this study came from these questionable codes and the estimates for
SO prevalence are likely over estimated because of their inclusion. Future studies can address these
uncertainties by verifying procedures performed by complete chart review. This technique is time
consuming and would limit the number of patients able to be studied, but is important for refining the
exact risk estimates. The advancement of electronic medical records and more specific ICD coding will
make this kind of confirmation more feasible in the future.
Additionally, because the KHCD data prior to 2004 are not available, the SO rates prior to 2004
were based on assumptions. This will certainly generate biases for the estimates. Although this study
requires a range of assumptions, it is reasonable to assume the true estimate is captured within the
variation of the estimates. There are no survival data available in the KHCD data, hence the 2010
US life table estimates with a 0.5% deduction were used to estimate the alive SO cases for specific
prevalence date and age groups. How much bias is introduced and in which direction this bias goes is
unknown. With increasing availability and reliability of health claims data, this approach will likely
provide more accurate estimates in the future. The BRFSS data are limited by sampling biases, recall
biases, and missing data. Overall, although we cannot provide specific rates for the SO estimates, we
can conclude that the corrected rates of ovarian cancer were substantially higher when SO was taken
into consideration than estimates from the standard population.
Finally, this study should be expanded to a broader national population as there may be important
differences between the population in Kentucky versus other parts of the nation.
In conclusion, this study presents an important concept for correcting the underestimation
of ovarian cancer risk for women who retain their ovaries and tubes. This correction has critical
implications for the calculation of screening program performance in terms of predictive value.
It is also critically important to refine the epidemiological assessment of the distribution of this
disease and the populations at risk so that the highest risk groups can be identified, which will
improve screening programs ability to reduce mortality from ovarian cancer while reducing harm
from unnecessary interventions.
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